Mato just raised pre-seed Read more
Podcast charts
Published by KCAS
"The Weekly Bioanalysis" is a podcast dedicated to discussing Bioanalytical news, tools and services related to the Pharmaceutical, Biopharmaceutical and Biomarker industries. Every month, KCAS will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they've learned about the Bioanalytical world the past couple of weeks. "The Weekly Bioanalysis" is brought to you by KCAS.KCAS is a progressive growing contract research organization of well over 200 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA and Milan, Italy, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the Pharmaceutical, Biopharmaceutical, Animal Health and Medical Device industries.
On the charts
Every published chart this podcast appears in, in the snapshot behind this page. Each one links to the chart it came off.
The Mato Topic Intelligence Platform does not report this podcast as charting in a published category in this snapshot.
From the feed
The latest episodes published to this podcast’s own RSS feed. Titles and descriptions are the publisher’s.
The main discussion in Episode #101 of “The Weekly Bioanalysis” focuses on how bioanalytical testing continues to evolve alongside increasingly complex drug modalities, with our co-hosts, Dom and John, exploring the technologies, methodologies, and regulatory trends shaping modern bioanalytical laboratories. They discuss how advances in mass spectrometry, including the transition to newer SCIEX 6500 and 7500 platforms, along with emerging technologies such as the Alamar NULISA system, are enabling dramatically greater sensitivity while requiring smaller sample volumes and supporting more challenging biomarker studies. The conversation also examines the growing importance of assay selectivity, fit-for-purpose validation strategies, and the industry's ongoing debate surrounding single replicate analysis versus traditional duplicate testing as laboratories seek to balance efficiency, cost, and scientific rigor. Throughout the discussion, the hosts emphasize that no single analytical platform solves every challenge, making it increasingly important for CROs to maintain a diverse suite of technologies capable of addressing a wide range of client needs. “The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they’ve learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio. KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.
In this special 100th episode of The Weekly Bioanalysis , hosts John Perkins and Dominic Warrino are joined on camera by KCAS Bio CEO John Bucksath and Chief Commercial Officer Amy Mize to celebrate a major milestone. Together, they reflect on the podcast's origins during the uncertainty of the COVID-19 pandemic and how it evolved into a trusted industry platform over the past six years. The conversation explores the remarkable growth of KCAS Bio, from a single local laboratory to a globally recognized bioanalytical partner with an expanding international presence. Along the way, the group discusses the role The Weekly Bioanalysis has played in strengthening industry connections, sharing scientific insights, and helping tell the KCAS Bio story. It's a fitting look back at the people, conversations, and achievements that helped shape both the podcast and the company over its first 100 episodes. “The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they’ve learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio. KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.
On this latest episode of The Weekly Bioanalysis podcast, Dom and John dive into one of the most pressing challenges in modern bioanalysis: how to break down silos and drive better project execution through continuity across teams. Drawing from real-world experience, they explore how the industry has evolved from isolated workflows toward more integrated approaches, especially as complex therapeutics like ADCs and emerging platforms push traditional boundaries. The conversation highlights the importance of early collaboration, seamless handoffs between development and validation, and the growing role of cross-functional scientific advisory teams in delivering consistent results. They also touch on emerging trends like microsampling and how innovation is reshaping both preclinical and clinical workflows. It’s a practical, behind-the-scenes look at what it really takes to execute successfully in today’s increasingly complex bioanalytical landscape. “The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they’ve learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio. KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.
In the newest episode of "The Weekly Bioanalysis" podcast, our hosts, John and Dom welcome Scott Weir (Director, Institute for Advancing Medical Innovation at KU Medical Center) for a practical, behind-the-scenes look at how drug discovery and development can be executed in an academic setting—and what it takes to translate promising lab or bedside discoveries into real clinical programs. Scott breaks down the process through three clear “pillars” that guide early development: does the drug reach the site of action, engage the target, and produce the intended pharmacologic response—from preclinical studies through early-phase trials. He also explains how KU builds a “virtual biotech” model by combining industry-experienced teams, university core infrastructure, and CRO partners like KCAS Bio, including a discussion of their “triple threat” CAR-T program (CD19/20/22) manufactured on-site in a GMP cellular therapy facility. The conversation goes deeper into the realities of cost, bioanalytical and biomarker needs across modalities, and how public–private partnerships help academic programs cross the “valley of death” from animal proof-of-concept to clinical proof-of-concept. “The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they’ve learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio. KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.
In episode #97 of “The Weekly Bioanalysis” podcast, John and Dom focus on a review of 2025 drug approvals, revealing a surprisingly strong year for small molecules despite long-standing predictions of their decline. Of the 53 FDA approvals, 31 were small molecules, with additional complexity coming from ADCs and RNAi therapies, underscoring the continued importance of small-molecule development and analytics. The hosts also compare U.S. and European approvals, noting meaningful differences driven by regulatory timing and regional priorities rather than scientific divergence. They highlight encouraging momentum in ADCs, the role of acquisitions in successful approvals, and a broad mix of indications—from rare diseases and oncology to neurology and vaccines. Overall, the episode reinforces that innovation remains diverse, with small molecules, large molecules, and conjugated technologies all playing critical roles in modern drug development. If you want a comprehensive view of the noteworthy approvals from 2025, this is the episode you’re looking for! “The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they’ve learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio. KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.
John and Dom introduce guest Brad Nawa (Alamar Biosciences) to explain the NULISA™ platform, an ultra-sensitive platform for protein quantitation that aims to outperform earlier “ultra-sensitive” tools that often didn’t translate well in practice. Brad notes the platform is still antibody/content-driven, but differentiates itself by reducing background through a dual-capture purification step and a nucleic-acid barcode/ligation readout, enabling scalable multiplexing (currently ~256-plex, with room to expand). They emphasize the fully automated ARGO™ HT system as a key advantage for minimizing operator variability and supporting strong instrument-to-instrument and lot-to-lot reproducibility. The discussion covers applications including biomarker discovery/monitoring, patient stratification, and PK/PD - especially when sample volume is limited or sensitivity is critical - and use across many matrices (plasma/serum/CSF, tissue lysates, vitreous humor, and dried blood/plasma spots with high recovery reported for most targets). They close by framing the future around building robust datasets for AI/meta-analysis, expanding therapeutic content (notably CNS/neurodegeneration, immunology, and cardiometabolic), and improving cloud software for pathway-level interpretation. “The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they’ve learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio. KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.
In the latest episode of the Weekly Bioanalysis podcast, Dom and John break down their biggest takeaways from the recent AAPS and EBF meetings, sharing what stood out across the scientific sessions, exhibition floors, and industry conversations. They discuss the major themes shaping bioanalysis right now, from emerging technologies to shifting regulatory expectations, and compare how each conference approached them. Our hosts also dive into evolving practices in biomarkers, immunogenicity, and complex modalities, highlighting where the field seems to be headed next. Finally, they offer candid reflections on the changing structure of professional communities and what that might mean for networking and scientific collaboration. It’s a wide-ranging, insider recap of two of the year’s most important events—well worth a listen for anyone tracking trends in bioanalytical science. “The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they’ve learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio. KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.
In this episode, hosts Dom and John welcome Jason Hannah, Director of Marketing at KCAS Bio, to discuss the company’s strategy for navigating the 2025 global conference season. With major events like AAPS PharmSci 360 in the U.S. and the European Bioanalysis Forum (EBF) in Barcelona on the horizon, Jason explains how KCAS approaches each with a structured, three-phase plan: pre-show planning, on-site activation, and post-show follow-up. He highlights the differences between large, trade show–focused meetings like AAPS and more intimate, science-driven gatherings like EBF, noting how KCAS Bio tailors its engagement and messaging to fit each audience. The conversation offers a behind-the-scenes look at how marketing and scientific teams align to make every conference a coordinated effort to strengthen relationships and showcase KCAS Bio’s leadership across the bioanalytical industry. “The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they’ve learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio. KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.
During episode #93 of The Weekly Bioanalysis , John and Dom welcome guest Chris Crean, founder/CEO of Xyzagen, who reflects on three decades in drug development and how the field has shifted from small molecules to today’s complex biologics, gene editing, and beyond. Chris explains how Xyzagen helps small, science-driven teams move faster by uniting early discovery “back-office” needs so studies are right-sized and decision-ready. He dives into modern PK design, showing how advances in LC-MS and immunoassays slash sample volumes and enable smarter rodent studies while preserving animal welfare. The conversation covers non-compartmental vs. modeling/simulation approaches and the practical toolset teams actually use plus when tissue distribution and ocular/CNS models matter. Chris also shares collaboration advice and highlights Xyzagen’s strengths in ophthalmology, neurology, and specialized routes like intrathecal or intravitreal dosing. “The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they’ve learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio. KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.
During episode #92 of The Weekly Bioanalysis , our hosts, John and Dom, dive into GLP-1 receptor agonists—originally developed for type 2 diabetes—and how their mechanisms (stimulating insulin, slowing gastric emptying, and reducing glucagon) also drive significant weight-loss effects. They discuss why native GLP-1 is too short-lived to be therapeutic and outline engineering strategies that extend half-life (e.g., fatty-acid albumin binding or Fc-fusion), walking through approved agents like exenatide, liraglutide, dulaglutide, lixisenatide, semaglutide, and tirzepatide (a dual GIP/GLP-1 agonist). Our hosts note bioanalytical implications of peptide size and structure, and common outcomes/side effects such as appetite suppression and occasional GI symptoms or nausea. We are excited to welcome John’s wife. Catherine, to the podcast for the first time. She joins to highlight her experiences and the real-world benefits of her GLP-1 treatments. The conversation closes by framing these drugs less as “weight-loss meds” and more as tools for broader metabolic health, with growing research and potential future indications. “The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they’ve learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio. KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.
In episode #91 of The Weekly Bioanalysis , John and Dom return to a two-person format to tackle the "gray areas" of bioanalysis, focusing on drug discovery, biomarkers, tissues, and emerging technologies. They discuss how traditional PK assay validation is highly standardized, but areas like early-stage discovery, biomarker qualification, and tissue analysis require more nuanced, fit-for-purpose approaches. A key theme is the need for flexibility and client collaboration, particularly when defining what constitutes validation versus qualification. The hosts emphasize how evolving technologies and commercially available reagents are enabling more streamlined, context-driven assays, though terminology differences—especially between U.S. and EU practices—continue to cause confusion. They close with a discussion on tissue assay limitations, particularly the inherent variability introduced during sample homogenization. “The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they’ve learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio. KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.
In this episode of “The Weekly Bioanalysis” podcast, our hosts, Dominic Warrino and John Perkins, sit down with two key leaders shaping the company’s future — Maria Nelson, Chief Financial Officer, and Julie Deane, Chief People Officer — to discuss KCAS Bio’s strategy for balancing rapid growth with an exceptional employee experience. Building on the previous conversation with Jeff Goddard, this episode dives deeper into how KCAS Bio has evolved its people operations and operational planning. Julie shares how private equity investment fueled a transformation in talent acquisition, creating a scalable, high-performing recruitment process that attracts thousands of candidates monthly while enhancing the KCAS Bio employer brand. Meanwhile, Maria explains the company’s internal forecasting model, CURE (Capacity Utilization Resource Evaluation), which enables proactive workforce planning to meet client demands without compromising efficiency. Together, they reveal how KCAS Bio blends scientific excellence with business strategy to grow responsibly and maintain its strong culture. “The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they’ve learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio. KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.
In Episode 89 of The Weekly Bioanalysis , hosts Dominic Warrino and John Perkins engage in a compelling conversation with special guest, Jeff Goddard, Senior Vice President of Corporate Development at KCAS Bio. The three delve into KCAS Bio's strategic growth, including the acquisition of France-based Active Biomarkers, which expanded the company's transatlantic presence. Jeff shares insights into the evolving landscape of bioanalytical services and how KCAS Bio is positioning itself to meet the challenges of modern drug development. The discussion also touches on the importance of collaboration and innovation in accelerating therapeutic discoveries. “The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they’ve learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio. KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.
In Episode 88 of The Weekly Bioanalysis , hosts Dominic Warrino and John Perkins present a special WRIB 2025 recap featuring several KCAS Bio scientists who share firsthand insights from their presentations at the major bioanalytical conference. Dave Ambrose highlights KCAS Bio’s global harmonization of spectral flow cytometry instruments across sites in the U.S., France, and Australia, showcasing the industry’s first off-the-shelf spectral flow panel with impressively tight inter-site CVs. Jessica Pham discusses her work on a VAMS-based PK assay for an anti-malarial monoclonal antibody, designed to enable microsampling in remote regions with high temperature stability. Bryan Parmentier presents a novel method for overcoming matrix effects in cisplatin assays by adding exogenous hemoglobin, a breakthrough inspired by clinical anemia observations. The episode concludes with a group discussion about the implications of new biomarker guidance from the FDA and ICH M10, sparking debate on validation standards, regulatory interpretations, and industry alignment. “The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they’ve learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio. KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.
In episode 87 of The Weekly Bioanalysis podcast, John Perkins and Dawn Dufield preview the upcoming WRIB conference, where KCAS Bio and Sciex will both have strong representation through scientific presentations, panels, and business development efforts. Special guest, Rahul Baghla of Sciex, discusses the company’s collaboration with KCAS Bio and introduces their high-throughput Echo technology, which uses acoustic ejection to improve speed and reduce carryover in early discovery assays. The conversation explores the evolution of mass spectrometry platforms, highlighting the robustness and sensitivity of Sciex’s 7500+ system and the increasing role of AI in streamlining data analysis. Dawn and John reflect on the challenges of adopting new technologies in regulated environments, emphasizing the balance between innovation and practical application. “The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they’ve learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio. KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.
During episode 86 of KCAS Bio's "The Weekly Bioanalysis" podcast, our hosts Dom and John are joined by Dr Cheikh Kane, the Vice President of Biopharma Services at KCAS Bio, to discuss immunogenicity. They first define Immunogenicity; what it is and why it is tested, as well as the standard approach for ADA testing before answering the question of "What is a 'Lean' anti-drug antibody (ADA) approach, and when should it be employed?". Dr Kane brings his decades of experience and biopharmaceutical expertise to a very impressive conversation that showcases the many options involved in ADA testing. This is one you won't want to miss! “The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they’ve learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio. KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.
Dom and John, the hosts of “The Weekly Bioanalysis”, recently returned from EBF in Barcelona where there was a session on Patient-centric Microsampling, which both of them founnd fascinating. This inspired both of them to decide it was high time to revisit this part of our industry. In spite of a few infamous setbacks caused by the dishonesty of a few bad actors within the industry a years ago, there has been a renewed interest in patient-centric sampling, and our hosts have invited one of the pioneers in this field, Dr Neil Spooner, to join them on episode #85 to discuss the recent advances in the reemerging science around microsampling. They discuss Dried Blood Spot Analysis, device-based sampling vs conventional assays, the devices currently available, and what all of this might mean for the future of bioanalysis. “The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they’ve learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio. KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.
In episode 84 of “The Weekly Bioanalysis”, our special guest, Bryan Parmentier, joins Dom and John to discuss his background and current role at KCAS Bio, offering insights into the field of small molecule method development. He delves into the typical challenges encountered when working with LC-MS analytes, and how the evolving role of LC-MS continues to shape the industry. Parmentier emphasizes the value of pre-validation in ensuring method robustness and shares lessons learned from developing methods for antibody-drug conjugate (ADC) payloads. He also details the revised KCAS Bio approach for method development of ADC payloads and the associated downstream validation experiments. This episode provides valuable insights for professionals involved in bioanalysis, particularly in the context of complex analytes and cutting-edge therapeutics. “The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they’ve learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio. KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.
The 2024 tradeshow and conference season is finally coming to a close for the pharmaceutical and biotech industry, and our road-weary traveling hosts, Dom and John have returned from their final event, the 2024 European Bioanalysis Forum (EBF) Open Symposium in Barcelona, Spain. EBF was founded in 2006 at the initiative of 12 pharmaceutical companies. The goal was to create a platform for discussions around science, day-to-day procedures, business tools, technologies and - last but not least - regulatory issues. The theme of the conference this year was “Taking the temperature of bioanalysis”, which is exactly what the guys have come back to discuss here for the 83rd episode of “The Weekly Bioanalysis” podcast! “The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they’ve learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio. KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.
It’s conference season! This is a busy, busy time of the year for the entire industry, when everyone comes together from around the world to share, listen and discuss the changes and advancements taking place in the business and science of the pharma and biotech space. During this episode of “The Weekly Bioanalysis”, our hosts, Dom and John, go over all the places – around the world – where the KCAS Bio team will be taking part in exhibitions, panels and presentations. From Europe to Australia and all over the U.S., KCAS Bio will be attending a number of events, conferences and trade shows, featuring all the great things our organization has been up to over the last year or so. There is so much to go over, and we hope to see you at many of these industry events! “The Weekly Bioanalysis” is a podcast dedicated to discussing bioanalytical news, tools and services related to the pharmaceutical, biopharmaceutical and biomarker industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Senior Scientific Advisors as they chat over coffee and discuss what they’ve learned about the bioanalytical world the past couple of weeks. “The Weekly Bioanalysis” is brought to you by KCAS Bio. KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.
Ranking source
Apple Podcasts rankings via the Mato Topic Intelligence Platform.
Observed September 11, 2026. Cached outside the daily freshness window; the positions keep the date they were taken on.
Apple and Apple Podcasts are trademarks of Apple Inc., registered in the U.S. and other countries.
Pairs with
Bring this source into Mato to read its transferable patterns, then turn them into an original show for your own audience.